Skip to main content
Caplight Logo









Biomunex Pharmaceuticals

Biomunex Pharmaceuticals

Private
ParisHealthcare & Life Scienceshttps://biomunex.com/

Last Round

VC Round

Sep 30, 2025

Total Funding Raised

$3.5M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Biomunex Pharmaceuticals is a biopharmaceutical company that specializes in the discovery and development of innovative immuno-therapeutics, including bi- and multi-specific antibodies for the treatment of cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Application

Keywords

bispecific antibodyimmuno-oncologyMAIT cell engagersantibody engineeringdrug discoverybiotech platformin-silico drug designmulti-specific antibodycancer immunotherapybiopharma licensingai-augmented drug discoveryprotein engineeringnext-gen biologicst-cell engagers

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Biomunex Pharmaceuticals Comparables

Compare Biomunex Pharmaceuticals with similar companies based on industry and business-model similarity.

Biomunex Pharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Sino Biopharmaceutical
78%
Merus N.V.
76%
TRIO Pharmaceuticals, Inc.
76%

Biomunex Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundSep 30, 2025
GrantNov 3, 2021
Series AFeb 16, 2021

Key People

Founding team and executive leadership

Stéphane MILOT

Chief Financial Officer

Executive Team

Biomunex Pharmaceuticals Investors

Notable investors and investment history

Biomunex Pharmaceuticals investors
InvestorRounds
Agence Nationale de la RechercheGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 19, 2026

    Monthly visitors increased 83% MoM.

  • May 8, 2026

    Grew 20% QoQ, from 15 to 18 employees.

Biomunex Pharmaceuticals Filings

Explore SEC and related filing metadata, where available.

Biomunex Pharmaceuticals filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Biomunex Pharmaceuticals's valuation, stock price, and market status.

Is Biomunex Pharmaceuticals a public or private company?

Biomunex Pharmaceuticals is a private company.

What is the current stock price of Biomunex Pharmaceuticals?

Biomunex Pharmaceuticals is a private company with no public stock price. No recent secondary market data is available.

How much is Biomunex Pharmaceuticals worth (valuation)?

Valuation information for Biomunex Pharmaceuticals is not publicly available.

Can I buy Biomunex Pharmaceuticals stock?

Biomunex Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Biomunex Pharmaceuticals's last funding round?

Biomunex Pharmaceuticals's most recent funding round was VC Round on September 30, 2025.

Who are the main investors in Biomunex Pharmaceuticals?

Key investors in Biomunex Pharmaceuticals include Agence Nationale de la Recherche.

Will Biomunex Pharmaceuticals IPO soon?

No public IPO plans have been announced for Biomunex Pharmaceuticals.

How can I track Biomunex Pharmaceuticals secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Biomunex Pharmaceuticals's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersParis
Employee Range16
Year Founded2014
Last FundingSep 30, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?